Transwell assay demonstrated that the downregulation of LINC01133 importantly strengthened the migration and invasion capabilities of ER+ breast cancer cells, whereas LINC01133 upregulation substantially reduced these abilities (Figures 2g, h). Here, LINC01133 is linked to breast carcinoma.